PTC Therapeutics

PTC Therapeutics manufactures and commercializes small molecule drugs for the treatment of infectious diseases and neuromuscular disorders. Read more

Stuart W. Peltz's photo - Founder & CEO of PTC Therapeutics

Founder & CEO

Stuart W. Peltz

CEO Approval Rating

96/100

Founded:

1998

Status:

PublicIndependent CompanyNASDAQPTCT

PTC THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Dicerna is one of PTC Therapeutics's top competitors. Dicerna was founded in 2006 in Lexington, Massachusetts. Like PTC Therapeutics, Dicerna also operates in the Pharmaceuticals industry. Dicerna generates $252.6M less revenue than PTC Therapeutics.

Cydan is a top competitor of PTC Therapeutics. Cydan was founded in 2013, and is headquartered in Cambridge, Massachusetts. Like PTC Therapeutics, Cydan also competes in the Biotechnology field. Cydan generates $425.4M less revenue vs. PTC Therapeutics.

Sarepta is seen as one of PTC Therapeutics's top competitors. Sarepta is headquartered in Cambridge, Massachusetts, and was founded in 1980. Like PTC Therapeutics, Sarepta also operates in the Pharmaceuticals field. Sarepta generates 113% the revenue of PTC Therapeutics.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Exonate a competitor of PTC Therapeutics?

PTC Therapeutics Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$430.4M

PTC Therapeutics's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 410.4M. Over the last four quarters, PTC Therapeutics's revenue has grown by 56.8%. Specifically, in Q1 2021's revenue was $117.9M; in Q4 2020, it was $118.9M; in Q3 2020, it was $118.4M; in Q2 2020, PTC Therapeutics's revenue was $75.2M.

PTC Therapeutics Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Censa Pharmaceuticals, Inc.

May 2020

Source »
$10M
Censa Pharmaceuticals develops and commercializes drugs for the treatment of phenylketonuria.
Agilis Biotherapeutics, Inc.

Jul 2018

Source »
$200M
Agilis is a biotechnology company that engages in developing gene-based therapeutics for rare monogenic diseases that affect the central nervous system.

These are all the companies that PTC Therapeutics has acquired. PTC Therapeutics has acquired 2 companies and its latest acquisition was Censa Pharmaceuticals, Inc. in May 2020. Censa Pharmaceuticals develops and commercializes drugs for the treatment of phenylketonuria.

PTC Therapeutics Funding History

Since PTC Therapeutics was founded in 1998, it has participated in 7 rounds of funding. In total PTC Therapeutics has raised $426.6M. PTC Therapeutics' last funding round was on Aug 2015 for a total of $125.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2015
$125M
-
IPO
Jun 2013
$125.6M

Series D
Mar 2013
$60M
Equity
Jul 2012
$30M
Series E
Dec 2009
$50M

Since PTC Therapeutics was founded in 1998, it has participated in 7 rounds of funding. In total PTC Therapeutics has raised $426.6M. PTC Therapeutics' last funding round was on Aug 2015 for a total of $125.0M

PTC Therapeutics Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

ClearPoint Neuro develops a deep-brain stimulation platform that enables therapies for the treatment of neurological disorders.
$7.5M
Dec 28, 2020
Convertible Note
-
ClearPoint Neuro develops a deep-brain stimulation platform that enables therapies for the treatment of neurological disorders.
$17.5M
Jan 12, 2020
Equity
-

These are all the companies that PTC Therapeutics has invested in. PTC Therapeutics has invested 2 companies and its latest investment was Censa Pharmaceuticals, Inc. in May 2020. Censa Pharmaceuticals develops and commercializes drugs for the treatment of phenylketonuria.

PTC Therapeutics News

May 4, 2021MarketScreener

Provides a Corporate Update and Reports First Quarter 2021 Financial Results

(marketscreener.com) PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Fina... See more »
April 20, 2021BioSpace

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference... See more »
April 19, 2021BioSpace

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 19, 2021

PTC Therapeutics, Inc. announced that on April 13, 2021 it approved non-statutory stock options to pu... See more »
April 15, 2021The Pharma Letter

Strong Evrysdi data keep coming in SMA

PTC Therapeutics has announced new data showing continued improvements in motor milestones in infants... See more »
April 15, 2021Clinical Trials Arena

PTC's Evrysdi improves motor function and survival in infants with SMA

The post PTC's Evrysdi improves motor function and survival in infants with SMA appeared first on Cl... See more »
April 8, 2021BioSpace

PTC Therapeutics Received Gallup's Don Clifton Strengths-Based Culture Award

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Do... See more »
April 7, 2021MarketScreener

to Host PTC518 Huntington Disease Deep Dive Webinar

(marketscreener.com) SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. wil... See more »

PTC Therapeutics Press Releases

February 17, 2021PR Newswire

PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19

SOUTH PLAINFIELD, N.J., Feb. 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today an... See more »
February 16, 2021PR Newswire

PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

SOUTH PLAINFIELD, N.J., Feb. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today ann... See more »
February 4, 2021PR Newswire

PTC Therapeutics to Host Call to Review Results from its Study of Translarna (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., Feb. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host ... See more »
November 19, 2020PR Newswire

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today ann... See more »
November 16, 2020PR Newswire

PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases

SOUTH PLAINFIELD, N.J., Nov. 16, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today ann... See more »
November 15, 2020PR Newswire Asia

PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19

- Oral treatment with novel dual-mechanism of action has the potential to address the two critical el... See more »
October 21, 2020PR Newswire

RareMed Solutions Announces that it has been Selected as the Non-Commercial Dispensing Pharmacy for EMFLAZA by PTC Therapeutics, Inc.

PITTSBURGH, Oct. 21, 2020 /PRNewswire/ -- RareMed Solutions announces that it has been selected by PT... See more »

PTC Therapeutics Videos

Social Media

PTC Therapeutics Headquarters

100 Corporate Court

South Plainfield, New Jersey07080

908-222-7000

Driving Directions »

Trending Companies

PTC Therapeutics Summary

ABOUT

Overview

PTC Therapeutics manufactures and commercializes small molecule drugs for the treatment of infectious diseases and neuromuscular disorders. PTC Therapeutics was founded in 1998. PTC Therapeutics' headquarters is located in South Plainfield, New Jersey...

CEO

PTC Therapeutics's Founder & CEO, Stuart W. Peltz, currently has an approval rating of 96%. PTC Therapeutics's primary competitors are Dicerna, Cydan & Sarepta.

Website

ptcbio.com

Frequently Asked Questions about PTC Therapeutics

  1. When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998
  2. Who is PTC Therapeutics's CEO?

    PTC Therapeutics's CEO is Stuart W. Peltz
  3. How much revenue does PTC Therapeutics generate?

    PTC Therapeutics generates $430.4M in revenue
  4. How much funding does PTC Therapeutics have?

    PTC Therapeutics has historically raised $426.6M in funding
  5. Where is PTC Therapeutics's headquarters?

    PTC Therapeutics's headquarters is in South Plainfield New Jersey, USA
  1. How many employees does PTC Therapeutics have?

    PTC Therapeutics has 517 employees
  2. What sector does PTC Therapeutics operate in?

    PTC Therapeutics is in Pharmaceuticals, Biotechnology
  3. Who are PTC Therapeutics's competitors?

    PTC Therapeutics's top competitors are Dicerna, Cydan, Sarepta
  4. Who has PTC Therapeutics invested in?

    PTC Therapeutics's has invested in companies such as ClearPoint Neuro, ClearPoint Neuro